Newly Created Role Demonstrates Commitment to Improve Diversity in Clinical Trials and Commercialization Across Organization MORRISVILLE, N.C., May 25, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced the
Healthcare Businesswomen’s Association Spotlights Jennifer Sozio and Caitlin Purinai for Biopharma Industry Impact MORRISVILLE, N.C., May 17, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq: SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced that Jennifer
Company Executives Honored for Notable Biopharmaceutical Industry Impact MORRISVILLE, N.C., May 16, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced PM360 has named Maria Fotiu, President, Sites and
Revenue for the first quarter of $1,356.8 million increased 1.5% on a reported basis and increased 2.4% on a constant currency basis year-over-year. Clinical Solutions net new business awards and book-to-bill ratios: Including reimbursable out-of-pocket expenses, $713.6 million for the first
Shareholders to Receive $43.00 Per Share in Cash Represents 24% Premium to Unaffected Stock Price MORRISVILLE, N.C., May 10, 2023 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (“Syneos Health” or the “Company”), a leading fully integrated biopharmaceutical solutions organization, today
Finance Leader with 30+ Years of Experience, Including 15 Years in Clinical Research Industry MORRISVILLE, N.C., May 02, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the appointment of Michael Bonello as
Company Recognized for Positive Vaccine Expertise Contributions MORRISVILLE, N.C., April 05, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced it has been awarded the Vaccine Industry Excellence Award for
MORRISVILLE, N.C., April 04, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq: SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced Jeanine O’Kane as President of Syneos Health Communications — a portfolio of agencies spanning advertising, public relations,
Program Drives Digital and Omnichannel Engagement for Medical Science Liaison Teams & Medical Conferences MORRISVILLE, N.C., March 27, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq: SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced the launch of Medical
Collaboration Will Leverage Data Analytics and AI to Accelerate Clinical Trial Execution MORRISVILLE, N.C., March 22, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced a strategic partnership with KX, maker
Collaboration Leverages AI-ready Technology to Speed Asset Development and Optimize Performance MORRISVILLE, N.C., March 20, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced a strategic multi-year agreement
Newly Established Network Will Enable High Quality DCTs & Digital Health Technology Solutions MORRISVILLE, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq: SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced the launch of a Decentralized
Revenue for the fourth quarter of $1,359.9 million decreased 1.0% on a reported basis and increased 1.7% on a constant currency basis year-over-year. Clinical Solutions net new business awards and book-to-bill ratios: Including reimbursable out-of-pocket expenses, $470.1 million for the fourth
MORRISVILLE, N.C., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its fourth quarter and full year 2022 financial results on Thursday, February 16, 2023, prior to its earnings call at 8:00 a.m. ET.
MORRISVILLE, N.C., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced a strategic partnership with Equicare to use proXimity™, an innovative cloud-based software platform that accelerates the transfer
Combined Capabilities Will Help Improve Trial Lifecycles for Patients, Sites & Sponsors MORRISVILLE, N.C., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq: SYNH), the only fully integrated biopharmaceutical solutions organization, today announced a strategic partnership with Haystack
Partnership to Provide Cell and Gene Industry Integrated Solution including Cryoport's IntegriCell™ platform, and Supply Chain Services NASHVILLE, Tenn. , Jan. 18, 2023 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) (" Cryoport "), a leading global provider of innovative temperature-controlled
MORRISVILLE, N.C. – January 16, 2023 – Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, announced that it has entered into a partnership with Clinical Research Malaysia (CRM), expanding the Company’s clinical trial capabilities across a broader
Relationship Will Leverage Syneos One Expertise, Accessing Clinical and Commercial Solutions MORRISVILLE, N.C., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced a strategic partnership with Fosun
Despite Uncertainties, Survey Hints that Dealmaking Intensity Could Be Poised for a Rebound After a Year of Inertia MORRISVILLE, N.C., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today released its 13 th annual
Reaffirms Full-Year 2022 Revenue Guidance MORRISVILLE, N.C., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq: SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that, effective March 31, 2023, Jason Meggs will transition from his role as Chief
MORRISVILLE, N.C., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that Chief Executive Officer Michelle Keefe is scheduled to present at the 41 st Annual J.P.
